TABLE 1.
Demographics and baseline clinical parameters of the study population
| Parameter | Total N = 104 |
|---|---|
| Male gender, n (%) | 76 (73) |
| Age, years | 71 ± 10 |
| Ischemic etiology, n (%) | 42 (40) |
| QRS duration, ms | 152 ± 26 |
| NYHA class | |
| Class I, n (%) | 2 (2) |
| Class II, n (%) | 46 (44) |
| Class III, n (%) | 53 (51) |
| Class IV, n (%) | 3 (3) |
| LV ejection fraction, % | 29 ± 7 |
| AF History, n (%) | 44 (42) |
| AF on implantation, n (%) | 23 (22) |
| Valvular disease, n (%) | 24 (23) |
| Diabetes, n (%) | 32 (31) |
| COPD, n (%) | 21 (19) |
| Chronic kidney disease, n (%) | 38 (36) |
| Hypertension, n (%) | 79 (76) |
| β‐Blocker use, n (%) | 97 (93) |
| ACE‐inhibitor use, n (%) | 54 (52) |
| Diuretic use, n (%) | 97 (93) |
| Antiarrhythmic use, n (%) | 27 (26) |
| Ivabradine use, n (%) | 12 (11) |
| CRT device, n (%) | 96 (92) |
| Primary prevention, n (%) | 101 (97) |
Abbreviations: ACE, angiotensin‐converting enzyme; AF, atrial fibrillation; COPD, chronic obstructive pulmonary disease; LV, left ventricular; NYHA, New York Heart Association.